New Industries Require New Insight
The microbiome and its role in human health represents a paradigm shift in how medicines will be developed. The PRI was founded to make Microbiotic Medicinal Products a therapeutic reality in Europe.
A Unique Collaborative Approach
The PRI, as a neutral and financially independent non-profit association, applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its members.
The Future of Human Health
The PRI believes that the microbiome is the future of human medicine. Our members have a stake in regulatory, technical and collaboration efforts of the microbiome & human health space.
First Vice President
Second Vice President
Meet the Team
Scientific & Regulatory Affairs Director
Microbiome Project Manager
Pharmabiotics Event Director
Membership in the PRI plays an important role in several of our members’ development & marketing strategies.
What are Microbiotic Medicinal Products (MMPs)?
The PRI defines MMPs as any medicinal product containing living, dead or fragments…, of components of the microbiome (i.e. bacteria, yeasts, phages, etc…) with the purpose to prevent or treat human diseases through a pharmacological, microbiological, neurological, immunological or metabolic mode of action, or make a medical diagnosis.
The PRI is Europe’s leading Microbiome Regulatory Expertise Center dedicated to supporting the development of microbiome-based medicines for the EU Market.
Find out more about the PRI from some of her members…
Our team is available to answer any questions you may have. Please contact us by phone or email us directly.